<DOC>
	<DOCNO>NCT02569827</DOCNO>
	<brief_summary>Dengue fever acute febrile illness transmit mosquito , affect half world 's population . There 96 million symptomatic infection , 500,0000 hospitalisation 25,000 death per year attribute disease . The economic burden $ 12 billion . In Singapore , elsewhere , incidence disease continue increase despite aggressive control measure . At present approved medicine treat dengue fever . Only supportive fluid replacement therapy use treat vascular leakage patient severe illness . Therefore urgent need find alternative treatment . Experiments laboratory show Celgosivir modipafant inhibit dengue virus improve mouse survival . Both drug previously use human good safety record , investigator take one step find well work dengue patient . Investigators plan enroll dengue patient within 48 hour fever onset assign one four treatment group five day . Together support industry partner , 60°Pharmaceuticals PLC , investigator determine safety effectiveness drug acute dengue patient pave way forward dengue antiviral medicine reach patient .</brief_summary>
	<brief_title>Celgosivir Modipafant Treatment Adult Participants With Uncomplicated Dengue Fever Singapore</brief_title>
	<detailed_description>This trial single centre , double-blind , double-dummy , placebo-controlled parallel-group , dose range study adult participant uncomplicated dengue fever . The study conduct two part : In Part 1 , 72 otherwise healthy participant ( 18 participant per group , assume 2 dropout per group ) uncomplicated dengue fever meeting inclusion/exclusion criterion randomise receive treatment placebo , celgosivir modipafant . Participants randomise parallel one Cohorts 1 4 : - Cohort 1 : Placebo Q6Hours 5 day - Cohort 2 : Modipafant 50 mg Q12Hours alternate placebo Q12Hours 5 day ( total 10 modipafant dos = 500 mg ) ; - Cohort 3 : Modipafant 100 mg Q12Hours alternate placebo Q12Hours 5 day ( total 10 modipafant dos = 1000 mg ) ; - Cohort 4 : Celgosivir 150 mg Q6H 5 day ( total 20 dos = 3000 mg total ) . As modipafant untested uncomplicated dengue fever patient , double-blinded sentinel group consist 4 participant randomise 1:1:1:1 ratio Cohort 1 : Cohort 2 : Cohort 3 : Cohort 4 complete treatment Study Day 5 prior continue enrolment remain participant . Remaining 68 participant enrol parallel double-blinded fashion . Participants evaluate screening ( &lt; 24 hour Study Day 1 ) Study Days 1-5 , 14 28 . Participants confine SingHealth Investigational Medicine Unit ( IMU ) screen end study assessment Study Day 5 return clinic Day 14 28 outpatient . All patient receive capsule Q6H 5 day prepare open-label pharmacist accord randomisation plan . Interim Analysis : The treatment regimen choose Part 2 base analysis Part 1 data . A detailed Statistical Analysis Plan ( SAP ) prepare approval Sponsor prior perform unblinded analysis presentation personnel designate blinded randomization . A data safety monitor board ( DSMB ) conduct blind review source verify safety data . If safety concern , independent statistician perform unblinded futility analysis preliminary efficacy data four cohort ; blind treatment group ( celgosivir modipafant ) maintain , however placebo unblinded . If futility conclude , Sponsor may elect discontinue study . If signal detect , sample size calculation undertaken Part 2 . The Sponsor convene Scientific Advisory Board ( SAB ) review unblinded log10 serum viral load AUC viraemia platelet count data recommend dose monotherapy dose regimen advance Part 2 . If recommend sample size Part 2 exceeds maximum specified Part 1 2 ( total combine sample size N = 132 participant ) monotherapy , Sponsor submit major amendment Institutional Review Board/ Health Science Authority ( IRB/HSA ) consideration prior initiate Part 2 . For Part 2 , 60 otherwise healthy participant uncomplicated dengue fever meeting inclusion/exclusion criterion assign randomised double-blind fashion : - Cohort 5 : ( ) celgosivir monotherapy 150 mg Q6H , OR ( ii ) modipafant monotherapy ( either 50 mg Q12H 100 mg Q12H ) - Cohort 6 : Placebo extension 5 day treatment .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<criteria>1 . Male female , age 2165 year ; 2 . Acute febrile illness two manifestation ( headache , retroorbital pain , myalgia , arthralgia , rash , haemorrhagic manifestation , leucopoenia ) occurrence location time confirm case dengue fever ; 3 . Fever ( &gt; 37.5°C ) history fever screen 4 . &lt; 48 hour fever history 5 . Positive NS1 strip assay reversetranscriptase polymerase chain reaction ( RTPCR ) . 6 . Able willing give write informed consent ; , 7 . Willing inpatient Study Screening Study Day 5 return hospital study Days 14 28 . 8 . Willing keep study diary Study Day 5 Day 14 . 1 . Clinical sign symptom severe dengue , : Severe abdominal pain ; Persistent vomiting ; CS fluid accumulation ; Mucosal bleeding ; Altered mental state ; Liver enlargement &gt; 2 cm ; Systolic blood pressure &lt; 90 mmHg ; Pulse pressure &lt; 20 mmHg . 2 . A person follow laboratory value : Haematocrit &gt; 52 % male ; &gt; 46 % female ; Aspartate alanine aminotransferase ( AST ALT ) &gt; 1000 U/L ; Room air oxygen saturation &lt; 95 % ; Absolute neutrophil count &lt; 1500/µL ; Platelet count &lt; 80,000/mm3 ; Creatinine &gt; 165 µmol/L male ; &gt; 130 µmol/L female ; Haemoglobin &lt; 13.0 g/dL male ; &lt; 11.0 g/dL female ; Total bilirubin &gt; 24 µmol/L ; Serum CPK &gt; 600 U/L . 3 . History presently active intestinal disorder peptic ulcer , intestinal ulcer , intestinal obstruction , intestinal hernia , ulcerative colitis , malabsorption syndrome , celiac disease , Roemheld 's syndrome ( gastroesophageal regurgitation disease ) Crohn 's disease ; 4 . Severe diarrhoea ( grade 2 high accord NIH clinical trial guideline ) ; 5 . Current usage anticoagulant drug include , limited , aspirin , warfarin clopidogrel ; 6 . Any CS acute illness within seven day prior first study drug administration ; 7 . History adverse reaction celgosivir , castanospermine , modipafant formulation excipients history severe drug food allergy ; 8 . Exposure new investigational drug within 30 day prior study drug administration ; 9 . CS abnormal physical examination unrelated dengue infection , chest Xray 12lead ECG screen QTc prolongation ( &gt; 450 msec ) ; 10 . Women child bear potential ( WOCBP ) pregnant , breast feeding unwilling avoid pregnancy use highly effective contraception ( &lt; 1 % failure rate per year ) include oral subcutaneous implantable hormonal contraceptive , condom , diaphragm , intrauterine system ( IUS ) , period experimental drug administer . Prospective WOCBP must negative pregnancy test ( point care ) . 11 . Male participant unwilling comply contraceptive requirement study detailed Section 4.7 ( i.e . abstinence , effective barrier contraception study 65 day last dose study drug ) . 12 . Current significant medical condition illness include cardiac arrhythmia , cardiomyopathy cardiac disease , asthma respiratory disease , diabetes mellitus , renal hepatic impairment , thyroid disease , Parkinson 's disease , epilepsy history unexplained blackout , immunocompromised state include know HIV infection , illness Investigator considers exclude patient , especially require continuation medication likely interaction study drug . 13 . Any condition would render informed consent invalid , limit ability participant comply study requirement . 14 . Any condition , opinion Investigator , would complicate compromise study wellbeing participant .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Uncomplicated Dengue Fever</keyword>
	<keyword>Treatment</keyword>
	<keyword>Phase Ib/IIa</keyword>
	<keyword>single centre</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>parallel-group dose range trial</keyword>
	<keyword>Modipafant</keyword>
	<keyword>Celgosivir</keyword>
</DOC>